The molecular and genetic mechanisms by which different single nucleotide 5 8 variant (SNV) alleles in specific genes, or at the same genetic locus, bring about 5 9 7 1 mutant mRNAs that are predicted to escape the nonsense mediated decay (NMD) 7 2 surveillance pathway, making a mutant protein that exerts a dominant negative 7 3 interference effect to FBN1 thus generating a gain-of-function (GoF) rather than a 7 4 loss-of-function (LoF) allele as in MFS. Overall, we provide direct evidence that a 7 5 dominant negative interaction of FBN1 potentially explains the distinct clinical 7 6 phenotype in MPLS patients through genetic and functional analysis of the first 7 7
centrifugation. Approximately 100 μ l of acid-washed cells were then added to each 2 1 7
well followed by 120 μ L lysis buffer (100 mM Tris pH 8, 1% Triton X-100, 50 mM 2 1 8 β -mercaptoethanol, 3% HALT protease inhibitor cocktail, 30 mM N-ethylmaleimide, 2 1 9 and 12.5 U/mL Benzonase nuclease). Blocks were then sealed with a rubber mat 2 2 0 (Nunc 276002) and shaken at max speed two times for 3 min on a Qiagen Tissuelyzer 2 2 1 2. To each well was then added 35 μ L 4X sample buffer (2X TAE, 20% glycerol, 8% 2 2 2 SDS, 0.01% bromophenol blue). The blocks were then vortexed briefly and allowed to 2 2 3 incubate at RT for three minutes, followed by centrifugation for 2 min at 3000 rcf to 2 2 4 remove cell debris. Electrophoresis and capillary blotting to Hybond ECL 2 2 5 nitrocellulose were performed as described. Proteins were transferred to a 2 2 6 polyvinylidene difluoride membrane and probed with well-characterized monoclonal 2 2 7 antibody of anti-Fibrillin 1 (Abcam ab124334, Cambridge, UK). less than 0.05 were considered statistically significant. All reagents and plasmids are available upon request. figshare. All mutations identified in this study have been submitted to the Clinvar 2 3 7 database (Accession ID: VCV000617941, VCV000617942, VCV000617943). curvature was 43 degrees, and she displayed a flat back and thoracolumbar kyphosis. standardized to age and body surface area). Skeletal system abnormalities such as long 2 5 0 and thin limbs, and arachnodactyly were observed in the proband. targeted NGS, and subsequently confirmed by further validation using an orthogonal 2 5 7 experimental approach of Sanger sequencing ( Fig.1E ). presented with pectus excavatum and scoliosis confirmed by radiologic imaging. in this proband ( Fig.1J ). 101 cm (P 25 ; -1SD), an extremely thin body habitus with a weight of 12 kg (P 3 , -3SD). Physical examination revealed bilateral arachnodactyly ( Fig.1M, N) , uneven 2 9 1 asymmetric back whilst bending and congenital dislocation of the hip joint. Whole-spine X ray examination displayed severe right thoracic scoliosis with a main fissures, epicanthus and astigmatism. However, there were no signs or symptoms of lack of subcutaneous fat, consistent with a lipodystrophy by physical exam, and a 3 0 0 subsequent bodily progeroid appearance. However, this proband did not meet revised and foot radiographs to potentially assess 'bone age' suggested bilateral Marfanoid-progeroid-lipodystrophy syndrome ( (c.8275_8291del; p.Glu2759Cysfs*9) in FBN1 was identified in the proband. We consequently confirmed this variant in subject XH601 and it was indeed de novo 3 1 6 through parental Sanger sequencing and trio analysis ( Fig.1S ). In addition to Sanger 3 1 7
sequencing validation, we also performed cloning sequencing on Subject XH601 to 3 1 8
further verify that this indel is subject to frame-shift variation (data not shown).
3 1 9
Moreover, these two allelic truncating variants of p.Tyr2596Thrfs*86 and 3 2 0 p.Glu2759Cysfs*9 were not present in ExAC, 1000 Genome, ESP6500 database, Ghent Criteria (LOEYS et al. 2010 ) are presented in Table 1 . The variant of Y2596Tfs*86 identified in XH253 was a single nucleotide 3 2 8
frameshift deletion leading to a premature termination codon (PTC) in Exon 64, while 3 2 9
E2759Cfs*9 identified in XH601 was a frameshift deletion leading to a PTC in Exon 3 3 0 66, the final exon of FBN1 ( Fig. 2A) . Although both variants are very close in linear 3 3 1 space, they may lead to distinct alterations to the FBN1 transcript. To investigate this 3 3 2 hypothesis, we performed NMD predictions of the two truncating variants on Y2596Tfs*86 is predicted to be degraded by NMD, i.e. NMD + , while E2759Cfs*9 is 3 3 5 predicted to escape NMD, i.e. NMD - (Fig. 2B) . Using the same analytical tools, we 3 3 6
further tested whether previously reported protein-truncating FBN1 frameshift the contention that the underlying disease mechanism in MPLS is the same and 3 4 2 distinct from MFS (Fig. 2B) . These findings implicate a mechanism distinct from To further determine if the mutant FBN1 protein in MPLS is able to lead to 3 4 9 dominant negative or GoF effects, plasmids expressing mutants 3 5 0
(pEGFP-FBN1-Tyr2596Thrfs*86; pEGFP-FBN1-Glu2759Cysfs*9) and WT plasmid 3 5 1
(pEGFP-FBN1) were co-transfected into HEK293T cells at a 1:1 ratio. After 48h of with a monoclonal FBN1-specific antibody. Remarkably, WT plasmid (EGFP-FBN1 3 5 7 fusions) had the SDS-resistance properties of an amyloidogenic protein structure.
3 5 8
Since amyloid formation is time-and concentration-dependent, we set the time of mechanism.
In addition, we observed that co-transfection of 3 6 5 pEGFP-FBN1-Tyr2596Thrfs*86 and WT plasmid presented a small fraction of 3 6 6 aggregated protein. As this fraction was less than that of the WT plasmid, it can be 3 6 7
suggested that Tyr2596Thrfs*86 may undergo an NMD mechanism thus leading to 3 6 8 FBN1 haploinsufficiency (Fig.3A) . Moreover, these variations in the range of particle Previous studies have demonstrated that deleterious FBN1 mutations causing Western blots compared to the WT plasmid ( Fig.3B, C) . This observation is consistent
with the contention that the TGF-β signaling pathway is perturbed in a 3 8 5 SMAD-dependent manner in all 3 subjects. in our cohort harbored a heterozygous de novo variant of E2759Cfs*9 in FBN1, which 3 9 5
is located in the final exon. Notably, our MPLS patients presented with from those that cause classical MFS. Most of such mutations will be anticipated to 4 5 8 escape NMD and we propose these to function via a potential mechanism between 4 5 9
GoF and dominant negative and not a LoF mechanism. 4 6 0
Fibrillin-1 acts as the precursor to a recently-described glucogenic hormone: amounts of mutated protein are therefore produced (INOUE et al. 2004 ), leading to a 4 7 4 dominant negative molecular mechanism and the severe MPLS disease phenotype. systemic processes of microfibrillar assembly and function. MPLS patient has functional effects in a SMAD-dependent manner in all 3 subjects.
8 7
Our study indicated that the two phenotypes associated with FBN1 mutations, phenotype of MPLS, which had its first report in the Chinese population, is caused by 4 9 0 nonsense mutations that produce truncated FBN1 mutant proteins. These proteins the mutated monomer derived from the mutant allele impairs the fundamental 4 9 7 structure of its wildtype protein derived from the normal allele counterpart. This negative interference is not restricted to enhanced proteolytic clearance of mutant 5 0 0 microfibrils over time (BRENN et al. 1996) , but rather could also occur at the level of with other syndromes/disorders in a phenotype-oriented approach that characterizes 5 1 0 much of clinical medicine practice (WHITE et al. 2018) .
1 1
In conclusion, we provide direct evidence of dominant negative effects of 5 1 2 truncating FBN1 variants predicted to escape NMD in MPLS patients. Our study 5 1 3 expands the mutational spectrum of FBN1 and highlights the potential molecular 5 1 4 mechanism for MPLS patients, which facilitates our understanding of hypersignaling, surgical intervention for cardiovascular complications or for 5 1 8 scoliosis), or early intervention.
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